Free Trial

Abeona Therapeutics (NASDAQ:ABEO) Director Faith Charles Acquires 15,000 Shares of Company Stock

Abeona Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Faith Charles bought 15,000 Abeona shares at an average of $2.29 each, spending $34,350. The purchase increased her direct stake by 8.5% to 191,407 shares.
  • Abeona reported a quarterly loss of $0.08 per share, better than the $0.17 loss analysts expected, but revenue of $13.49 million fell short of the $14.82 million consensus.
  • Analyst sentiment was mixed but tilted positive: five analysts rated the stock Buy and one rated it Sell, for a MarketBeat consensus of “Moderate Buy” and an average price target of $21.
  • Five stocks we like better than Abeona Therapeutics.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Faith Charles purchased 15,000 shares of the company's stock in a transaction that occurred on Friday, November 13th. The shares were purchased at an average cost of $2.29 per share, for a total transaction of $34,350.00. Following the purchase, the director directly owned 191,407 shares in the company, valued at $438,322.03. This trade represents a 8.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Abeona Therapeutics Price Performance

Shares of ABEO stock opened at $2.42 on Monday. Abeona Therapeutics Inc. has a 12 month low of $2.09 and a 12 month high of $7.65. The firm has a market capitalization of $138.30 million, a P/E ratio of -2.26 and a beta of 1.50. The company's fifty day moving average price is $4.70 and its two-hundred day moving average price is $5.39.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The company had revenue of $13.49 million during the quarter, compared to analysts' expectations of $14.82 million. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%. On average, sell-side analysts anticipate that Abeona Therapeutics Inc. will post -0.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. UBS Group reissued a "buy" rating on shares of Abeona Therapeutics in a report on Friday, September 25th. Weiss Ratings downgraded Abeona Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Tuesday, November 10th. Oppenheimer restated an "outperform" rating and set a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Cantor Fitzgerald upped their target price on Abeona Therapeutics from $28.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, September 18th. Finally, Roth Capital started coverage on Abeona Therapeutics in a research note on Thursday, September 17th. They set a "buy" rating and a $17.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Abeona Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $21.00.

View Our Latest Research Report on ABEO

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its position in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 2,155 shares in the last quarter. Rangeley Capital LLC raised its position in shares of Abeona Therapeutics by 4.2% during the 1st quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company's stock valued at $269,000 after acquiring an additional 2,400 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Abeona Therapeutics by 1,026.2% during the 3rd quarter. Global Retirement Partners LLC now owns 4,978 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 4,536 shares in the last quarter. Pale Fire Capital SE lifted its stake in Abeona Therapeutics by 17.3% during the second quarter. Pale Fire Capital SE now owns 81,945 shares of the biopharmaceutical company's stock worth $506,000 after purchasing an additional 12,100 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in Abeona Therapeutics during the first quarter worth $154,000. Institutional investors own 80.56% of the company's stock.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company's lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient's skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

See Also

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abeona Therapeutics Right Now?

Before you consider Abeona Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.

While Abeona Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines